Insilico Medicine (2546.HK)

Type: Public AI drug discovery company — HK Stock Exchange, ticker 2546.HK

Insilico Medicine is the furthest-advanced AI drug discovery company by clinical pipeline depth. Its Chemistry42 platform uses generative AI for de novo small-molecule design, and its PandaOmics platform handles AI-based target identification from multi-omics data. The company operates an end-to-end AI drug discovery model: target identification → molecule generation → synthesis prioritization → clinical development, all AI-augmented.

Rentosertib — the sector's bellwether

Rentosertib (formerly ISM001-055) is a first-in-class TNIK inhibitor for idiopathic pulmonary fibrosis (IPF), discovered and developed using Insilico's AI platform. Key milestones:

• Discovery process: 18 months from project start to development candidate; <80 small molecules synthesized and tested (vs ~2,500 typical for traditional discovery)
• Phase IIa trial (GENESIS-IPF): Published in Nature Medicine, June 2025; positive results, improved lung function in 71 patients — the world's first Phase IIa proof-of-concept for AI-driven drug discovery efficacy
• 2026 status: Approaching Phase 3. Expected to become the first AI-designed drug to enter Phase 3 clinical trials. Multiple Phase 2b/3 studies planned for 2026–2027.
• April 2026: Rentosertib inhalation solution received IND clearance from China's CDE (13th program from Insilico's pipeline to receive IND clearance)

Sources: Chemistry World on Rentosertib Phase 3, Insilico Nature Medicine publication

Key deal

• Eli Lilly $2.75B deal — Lilly licensed Insilico's AI platform + specific programs; deal value reflects Phase IIa proof-of-concept premium. (IntuitionLabs Lilly-Insilico analysis)

LabClaw (Apr 2026)

Insilico launched LabClaw in April 2026 — an integrated agentic AI system with 5 collaborative AI agents and 28 specialized skill modules, creating a closed loop from target discovery → compound screening → automated wet-lab execution → data analysis. This is Insilico's lab-in-the-loop implementation.

What to watch

• Phase 3 design announcement for Rentosertib (expected 2026)
• FDA approval would be the first for any AI-designed drug in history
• Whether TNIK inhibition generalizes beyond IPF (other fibrotic diseases)